Skip to content
Screener

aTyr Pharma ATYR Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$152.27B+14.9%
Merck & Co. logo
Merck & Co.MRK
$367.21B+59.3%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$646.16M+211%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$1.37B+290%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$2.28B+84.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$1.77B+1,855%

Other financials

Income statement

See full
Revenue-
Operating income-$10.9M+46.4%
Net income-$10.3M+47.2%
EPS (diluted)-$0.11+50.0%

Balance sheet

See full
Cash & equivalents$16.2M-6.2%
Total debt$11.8M-10.7%
Total equity$48.8M-34.8%
Total assets$69.8M-31.2%

Cash flow

See full
Operating cash flow-$9.4M+32.7%
CapEx$73.0K+711%
Free cash flow-$9.4M+32.2%

Valuation

See full
Market cap$50.14M-89.6%

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-98.4%+18.0pp
Debt / equity0.2×+0.1×
Current ratio5.1×-0.5×

Where this comes from

Calculated from aTyr Pharma’s reported figures.

The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026. Open the filing →

Filed
Aug 7, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001339970-26-000053

FAQ

What is aTyr Pharma's enterprise value?
aTyr Pharma (ATYR) reported enterprise value of $54.17M in Q2 2026.
How has aTyr Pharma's enterprise value changed year-over-year?
aTyr Pharma's enterprise value decreased by 88.4% year-over-year, from $468.63M to $54.17M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about aTyr Pharma's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude